Cargando…

Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson’s Disease

Plasma low density lipoprotein (LDL) cholesterol has been associated both with risk of Parkinson’s disease (PD) and with age-related changes in cognitive function. This prospective study examined the relationship between baseline plasma LDL-cholesterol and cognitive changes in PD and matched Control...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sterling, Nicholas W., Lichtenstein, Maya, Lee, Eun-Young, Lewis, Mechelle M., Evans, Alicia, Eslinger, Paul J., Du, Guangwei, Gao, Xiang, Chen, Honglei, Kong, Lan, Huang, Xuemei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JKL International LLC 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898920/ https://www.ncbi.nlm.nih.gov/pubmed/27330838 http://dx.doi.org/10.14336/AD.2015.1030

Ejemplares similares

Serum Cholesterol and Nigrostriatal R2* Values in Parkinson's Disease
por: Du, Guangwei, et al.
Publicado: (2012)

Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson’s Risk
por: Zhang, Lijun, et al.
Publicado: (2017)

Predicting the multi-domain progression of Parkinson’s disease: a Bayesian multivariate generalized linear mixed-effect model
por: Wang, Ming, et al.
Publicado: (2017)

LDL cholesterol is associated with higher AD neuropathology burden independent of APOE
por: Wingo, Aliza P, et al.
Publicado: (2022)

Low plasma serotonin linked to higher nigral iron in Parkinson’s disease
por: Jellen, Leslie C., et al.
Publicado: (2021)

Is the fine motor–executive functions link stronger for new compared to repeated fine motor tasks?
por: Maurer, Michelle N., et al.
Publicado: (2020)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Targeting LDL Cholesterol With LNA
por: Krieg, Arthur M
Publicado: (2012)

Cellular itinerary of LDL cholesterol
por: Vance, Jean E.
Publicado: (2022)

Serum Cholesterol and the Progression of Parkinson's Disease: Results from DATATOP
por: Huang, Xuemei, et al.
Publicado: (2011)

Friedewald’s equation for calculating LDL-cholesterol: Is it the time to say “Goodbye” and adopt direct LDL cholesterol methods?
por: Khan, Sikandar Hayat, et al.
Publicado: (2019)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
por: Contois, John H., et al.
Publicado: (2023)

To What Extent Can Motor Imagery Replace Motor Execution While Learning a Fine Motor Skill?
por: Sobierajewicz, Jagna, et al.
Publicado: (2016)

Higher Non-High-Density Lipoprotein Cholesterol Was Higher Associated With Cardiovascular Disease Comparing Higher LDL-C in Nine Years Follow Up: Cohort Study
por: Hong, Sangmo, et al.
Publicado: (2023)

The effects of serum cholesterol, LDL, and HDL levels on gallstone cholesterol concentration
por: Atamanalp, S. Selcuk, et al.
Publicado: (2013)

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides
por: Higashi, Yukihito
Publicado: (2023)

LDL cholesterol estimation in patients with the metabolic syndrome
por: Gazi, Irene, et al.
Publicado: (2006)

LDL Cholesterol and Dysglycemia: an Intriguing Physiological Relationship
por: Merino, Jordi, et al.
Publicado: (2020)

LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

Addressing dyslipidemic risk beyond LDL-cholesterol
por: Tall, Alan R., et al.
Publicado: (2022)

Comparison of calculated LDL-cholesterol using the Friedewald formula and de Cordova formula with a directly measured LDL-cholesterol in Nepalese population
por: Pradhan, Santosh, et al.
Publicado: (2020)

The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk
por: Cesena, Fernando Henpin Yue, et al.
Publicado: (2017)

Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol
por: Fukuyama, Naoto, et al.
Publicado: (2008)

Impact of oxLDL on Cholesterol-Rich Membrane Rafts
por: Levitan, Irena, et al.
Publicado: (2011)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Postprandial decrease in LDL-cholesterol in men with metabolic syndrome
por: Skoczyńska, Anna, et al.
Publicado: (2015)

Korean public and hospital data for estimating LDL-cholesterol
por: Lee, Taesic, et al.
Publicado: (2018)

LDL–cholesterol transport to the endoplasmic reticulum: current concepts
por: Pfisterer, Simon G., et al.
Publicado: (2016)

Intuitive Modification of the Friedewald Formula for Calculation of LDL-Cholesterol
por: Hong, Jinyoung, et al.
Publicado: (2023)

Comparison of Newly Proposed LDL-Cholesterol Estimation Equations
por: Jeong, Yong Whi, et al.
Publicado: (2023)

Non-HDL Cholesterol is a More Superior Predictor of Small-Dense LDL Cholesterol than LDL Cholesterol in Japanese Subjects with TG Levels <400 mg/dL
por: Moriyama, Kengo, et al.
Publicado: (2016)

An fNIRS Study of Brain Lateralization During Observation and Execution of a Fine Motor Task
por: Khaksari, Kosar, et al.
Publicado: (2022)

ApoB and Non‐HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk
por: Johannesen, Camilla D. L., et al.
Publicado: (2022)

Longitudinal association of remnant cholesterol with joint arteriosclerosis and atherosclerosis progression beyond LDL cholesterol
por: Wu, Zhiyuan, et al.
Publicado: (2023)

Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease
por: Heilman, Patrick L., et al.
Publicado: (2020)

Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation
por: Cannet, Claire, et al.
Publicado: (2020)

Shape (but not volume) changes in the thalami in Parkinson disease
por: McKeown, Martin J, et al.
Publicado: (2008)

Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
por: Lewis, Mechelle M., et al.
Publicado: (2023)

LDL-cholesterol concentrations: a genome-wide association study
por: Sandhu, Manjinder S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_p8tg4984jt72o2mvgq9hor73om